Advanced Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Peripheral T Cell Lymphoma
Conditions
Brief summary
This study is a Phase I/IIa, multi-center, open-label study of BR1733 with a dose escalation part followed by a dose expansion part in adult subjects with advanced cancers. This treatment to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment will be administered until the subject experiences unacceptable toxicity, progressive disease, and/or has treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.
Detailed description
This is a multi-center, nonrandomized, open-label study to evaluate the safety, tolerability, pharmacokinetics/ pharmacodynamics, and efficacy of BR1733 in patients with advance cancer, such as recurrent/refractory follicular lymphoma, peripheral T cell lymphoma(PTCL), diffuse large B cell lymphoma(DLBCL) and advance solid tumors. Phase Ⅰ (Dose Escalation Phase): According to the incidence of DLT in BR1733 tablets in the treatment of advanced cancers, MTD and the Phase 2 clinical trial dose (RP2D) combining PK, PD, efficacy and safety data were determined. Phase IIa (Dose expansion stage): Evaluate the efficacy and safety of BR1733 monotherapy (Cohorts 1-5) in five separate cohorts.
Interventions
DRUGBR1733
Subjects will receive oral administration of BR1733.
Sponsors
Shanghai Blueray Biopharma Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Sign informed consent voluntarily. 2. Subjects with PTCL, DLBCL or advance solid tumors diagnosed by histology or cytology，whose disease progressed after standard treatment or have no standard treatment. 3. ECOG≤2. 4. Expected survival period ≥ 3 months. 5. Adequate organ function reserve at baseline.
Exclusion criteria
1. Subjects with symptomatic central nervous system (CNS) metastases or carcinomatous meningitis; 2. Subjects with a history of other primary malignancies within 5 years (except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumor), subjects with other primary tumors who had no evidence of disease for 5 years or more and did not require treatment could participate in the study; 3. Subjects with any severe uncontrolled disease such as liver disease such as cirrhosis, decompensated liver disease, kidney failure needs for hemodialysis or peritoneal dialysis, etc. 4. Subjects with HIV disease or a positive HIV test; or active hepatitis. 5. Subjects with organ transplantation (apart from keratoplasty) or allogeneic hematopoietic stem cell transplantation. 6. Subjects with impaired or clinically significant cardiac cerebrovascular disease. 7. Subjects known to be allergic to experimental drugs or similar compounds. 8. Subjects known with psychotropic substance abuse, alcohol or drug abuse, or mental disorders. 9. Any previous treatment with other EED inhibitors (e.g., MAK683, FTX-6058, etc.). 10. Females who are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity (DLT, Phase Ⅰ only) | 28 day cycle of therapy | To assess adverse events as dose limiting toxicities as defined by the protocol. |
| Objective Response Rate (ORR, Phase Ⅱa) | 24 months | The proportion of patients with a best response of at least partial remission (including partial remission and complete remission) using disease appropriate standardized response criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum plasma concentration (Cmax) of BR1733 monotherapy | 28 day cycle of therapy | Pharmacokinetics profile of BR1733 (plasma): Maximum plasma concentration (Cmax) |
| Area under curve, steady state (AUCss) of BR1733 monotherapy | 28 day cycle of therapy | Pharmacokinetics profile of continuous medication of BR1733 (plasma): Area under curve, steady state (AUCss) |
| Maximum plasma concentration, steady state (Cmax,ss) of BR1733 monotherapy | 28 day cycle of therapy | Pharmacokinetics profile of continuous medication of BR1733 (plasma): Maximum plasma concentration, steady state (Cmax,ss) |
| Clearance/ bioavailability (CL/F) of BR1733 monotherapy | 28 day cycle of therapy | Pharmacokinetics profile of BR1733 (plasma): Clearance/bioavailability (CL/F) |
| Halflife (T1/2) of BR1733 monotherapy | 28 day cycle of therapy | Pharmacokinetics profile of BR1733 (plasma): Halflife (T1/2) |
| Duration of Response (DoR) | Up to 2 years | DoR is defined as the duration (days) from initial response to disease relapse, progression, or death due to any course. |
| Overall Survival (OS) | Up to 2 years | OS is defined as the interval of time between the date of first treatment until death, loss to follow up or termination of the study by the sponsor |
| Progression-free survival (PFS) | Up to 2 years | PFS is defined as the interval of time between the date of first treatment to the earliest date of disease progression or death which occurs first |
| Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability | Up to 2 years | Adverse events assessed according to NCI-CTCAE v5.0 criteria. |
| Area under curve (AUC) of BR1733 monotherapy | 28 day cycle of therapy | Pharmacokinetics profile of BR1733 (plasma): Area under curve (AUC) |
Countries
China
Outcome results
None listed